Reproductive endocrinology

Pathophysiology-based classification of male infertility: evidence from an 800-patient prospective cohort

J Clin Endocrinol MetabPublished Prospective cohort study

Authors' conclusion

Comprehensive phenotyping markedly reduces the proportion of patients classified as having idiopathic infertility and identifies clinically relevant subgroups.

Study context

Population
Male partners of infertile couples, evaluated October 2024–January 2026, after exclusion of isolated female factor infertility
Participants
800 participants
Outcome
Prevalence of male factor infertility (MFI) categories, hormonal patterns across phenotypes, and proportion of idiopathic infertility after comprehensive work-up
Methodological detailsmonocentric, tertiary referral academic centre, Standardized clinical evaluation, hormonal assessment (total testosterone, FSH, LH), testicular US and complete semen analysis in all; microbiological testing, transrectal US and genetic analyses per guidelines
  • Monocentric
  • Tertiary referral academic centre
  • Standardized clinical evaluation, hormonal assessment (total testosterone, FSH, LH), testicular US and complete semen analysis in all; microbiological testing, transrectal US and genetic analyses per guidelines

Main finding

As reported in the abstract

Prevalence of MFI categories

Primary spermatogenic failure (most prevalent)

56.0%

Infection/inflammation

22.4%

Hypogonadotropic hypogonadism

8.5%

Idiopathic infertility

5.3%

Observational data: associations, not effects.

Further findings

Endocrine profiles across phenotypes

Distinct endocrine profiles; high-FSH spermatogenic failure the dominant phenotype

Original publication

Pathophysiology-based classification of male infertility: evidence from an 800-patient prospective cohort. J Clin Endocrinol Metab. Published 4 July 2026. doi:10.1210/clinem/dgag263

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.